Isomorphic Labs has closed a $5 billion Series C funding round led by Greenoaks and Sequoia Capital. The company plans to use the capital to scale its proprietary AI drug design engine, IsoDDE, and transition its internal oncology and immunology candidates into clinical trials.
Alphabet is the only listed company named: it invested significantly again in Isomorphic Labs' $5 billion Series C. For Alphabet, a large market-cap company, the size of this follow-on stake is not disclosed and is unlikely to move the share price. Isomorphic Labs itself is private, so the headline round is not directly tradable.